menu
    • menu
    [{"orgOrder":0,"company":"WCCT Global","sponsor":"ImmunoMolecular Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMT-002","moa":"Adrenergic-alpha-2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"WCCT Global","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NGP 555","moa":"Gamma-secretase (GS)","graph1":"Neurology","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"MOD-4023","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"10","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"Vaxart","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Norwalk GI.1 Virus","moa":"Norwalk GI.1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WCCT Global \/ Vaxart","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ Vaxart"},{"orgOrder":0,"company":"WCCT Global","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"10","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"WCCT Global","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MT1013","moa":"PTH1R","graph1":"Undisclosed","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"Pulmotect","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PUL-042","moa":"Toll-like-9 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"Stanford University | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Live, Wild-Type A\/california\/H1 N1 2009 Influenza Virus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WCCT Global \/ Stanford University | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ Stanford University | National Institutes of Health"},{"orgOrder":0,"company":"WCCT Global","sponsor":"Dance Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"WCCT Global \/ Dance Biopharm","highestDevelopmentStatusID":"8","companyTruncated":"WCCT Global \/ Dance Biopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by WCCT Global

    Menu

    WCCT Global

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT1013

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Shaanxi Micot Technology Limited Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MT1013 Clinical TRIAL In Healthy Subject

                            Details : MT1013 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 05, 2021

                            Lead Product(s) : MT1013

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Shaanxi Micot Technology Limited Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMT-002

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : ImmunoMolecular Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

                            Details : IMT-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 12, 2020

                            Lead Product(s) : IMT-002

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : ImmunoMolecular Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Stanford University | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus

                            Details : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 27, 2019

                            Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Stanford University | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norwalk GI.1 Virus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Vaxart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

                            Details : Norwalk GI.1 Virus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Caliciviridae Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 26, 2018

                            Lead Product(s) : Norwalk GI.1 Virus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Vaxart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Dance Biopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

                            Details : Human Insulin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 11, 2017

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Dance Biopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Novan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

                            Details : SB204 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2016

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Novan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PUL-042

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Pulmotect

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

                            Details : PUL-042 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 02, 2015

                            Lead Product(s) : PUL-042

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Pulmotect

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NGP 555

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : NeuroGenetic Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

                            Details : NGP 555 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 02, 2015

                            Lead Product(s) : NGP 555

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : NeuroGenetic Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOD-4023

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : OPKO Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy ...

                            Details : MOD-4023 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dwarfism, Pituitary.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 16, 2015

                            Lead Product(s) : MOD-4023

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : OPKO Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth